Rhythm Pharmaceuticals (RYTM) Stock Jumps 36.6%: Will It Continue to Soar?Zacks Investment Research • 07/10/25
Rhythm Pharmaceuticals, Inc. Announces Pricing of Upsized Public Offering of Common StockGlobeNewsWire • 07/10/25
Rhythm Pharmaceuticals, Inc. Announces Proposed Public Offering of Common StockGlobeNewsWire • 07/09/25
Rhythm Pharma Surges To Record High On 'Impressive' Results In ObesityInvestors Business Daily • 07/09/25
Rhythm Pharmaceuticals Announces Oral MC4R Agonist Bivamelagon Achieved Statistically Significant, Clinically Meaningful BMI Reductions in Placebo-controlled Phase 2 Trial in Acquired Hypothalamic ObesityGlobeNewsWire • 07/09/25
Rhythm Pharmaceuticals To Announce Topline Results from Phase 2 Trial Evaluating Oral MC4R Agonist Bivamelagon in Acquired Hypothalamic ObesityGlobeNewsWire • 07/08/25
Rhythm Pharmaceuticals: Rare Genetic Obesity Pioneer With Excellent ProspectsSeeking Alpha • 06/30/25
Rhythm Pharmaceuticals Announces Three Late-breaking Data Abstracts Accepted for Presentation at ENDO 2025GlobeNewsWire • 06/25/25
Rhythm Pharmaceuticals Announces New Data Presentations on Patients with Acquired or Congenital Hypothalamic Obesity (N=35) Treated with Setmelanotide for up to Nine Months in French Early-access ProgramGlobeNewsWire • 05/14/25
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Lags Revenue EstimatesZacks Investment Research • 05/07/25
Rhythm Pharmaceuticals Reports First Quarter 2025 Financial Results and Business UpdateGlobeNewsWire • 05/07/25
Will Rhythm Pharmaceuticals, Inc. (RYTM) Report Negative Earnings Next Week? What You Should KnowZacks Investment Research • 04/30/25
Rhythm Pharmaceuticals (RYTM) Moves 5.2% Higher: Will This Strength Last?Zacks Investment Research • 04/25/25
Rhythm Pharmaceuticals to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025GlobeNewsWire • 04/23/25
RYTM Stock Rises 17% on Meeting Goals in Hypothalamic Obesity StudyZacks Investment Research • 04/08/25
Rhythm Pharmaceuticals (RYTM) Surges 17.1%: Is This an Indication of Further Gains?Zacks Investment Research • 04/08/25
Rhythm Pharmaceuticals' drug for rare obesity disorder meets main goal in late-stage trialReuters • 04/07/25
Rhythm Pharmaceuticals Announces Pivotal Phase 3 TRANSCEND Trial Meets Primary Endpoint with -19.8% Placebo-adjusted BMI Reduction in Patients (N=120) with Acquired Hypothalamic ObesityGlobeNewsWire • 04/07/25
Rhythm Pharmaceuticals to Announce Topline Results from Pivotal Phase 3 TRANSCEND Trial Evaluating Setmelanotide in Patients with Acquired Hypothalamic ObesityGlobeNewsWire • 04/06/25
Rhythm Pharmaceuticals Reacquires Licensing Rights to IMCIVREE® (setmelanotide) in China with Termination of Agreement with RareStone Ltd.GlobeNewsWire • 03/20/25
Rhythm Pharmaceuticals Announces Orphan Drug Designation Granted to Setmelanotide for Treatment of Hypothalamic Obesity in JapanGlobeNewsWire • 03/19/25
Rhythm Pharmaceuticals and Raymond A. Wood Foundation Announce Research CollaborationGlobeNewsWire • 03/18/25